Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

MASH's economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of ...

A cross-sectional study of cardiovascular devices subject to Class I recalls from 2013 through 2022, found that most recalled devices did not undergo clinical testing before authorization and were not ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

The gut microbiome has been well-established in its role of regulating the onset of many gastrointestinal disorders. Recent ...

Atea Pharmaceuticals Inc. (NASDAQ:AVIR) announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

In California, the animal you run over cannot be carted off to your freezer. It must stay by the side of the road. California ...

The gut microbiota and its functional metabolites play crucial roles in the development of intestinal fibrosis in patients ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated price ...